Business Trends

Jan 01, 2005
BioPharm International
By BioPharm International Editors
For years, the pharmaceutical sector has provided a safe haven for investors. I'm not so sure that will be the case in 2005.
Jan 01, 2005
BioPharm International
By BioPharm International Editors
In the increasingly competitive world of drug discovery and development, the role of branding is more important than ever. With all the various sectors — big pharma, generics, specialty pharma, and biotechnology —vying for limited dollars, branding must begin early in the development process and, ultimately, play an integral role not only in taking a product to market, but also in sustaining that product against competition, perceived and real.
Dec 01, 2004
BioPharm International
By BioPharm International Editors
The holidays are upon us. It's the time of year that begins with gala parties in December and ends when you finally realize what you spent, usually around April 15 of the next year. Too Scrooge-like? Hope not. I just partook of some bad eggnog.
Nov 01, 2004
BioPharm International
By BioPharm International Editors
Over the last five years, alternative investments have been the fastest growing investment strategy in institutional investment markets.
Nov 01, 2004
BioPharm International
By BioPharm International Editors
A German biotechnology company based in Martinsried, GPC Biotech, raised €78.6 million in June through public and private placements in Germany, the US, and other countries. "Our recent financing was one of the most successful biotech offerings in terms of proceeds for the year to date, on either side of the Atlantic," said Dr. Bernd Seizinger, CEO of GPC. It is now one of the few German biotechnology companies listed on NASDAQ.
Oct 01, 2004
BioPharm International
By BioPharm International Editors
Identifying issues in the factory that traditionally arise in the field minimized onsite equipment rework and subsequent qualification work.
Oct 01, 2004
BioPharm International
By BioPharm International Editors
Though still relatively modest by international standards, the Netherlands' biotechnology industry has made impressive gains in recent years and now provides investors with a compelling alternative to more established European "heavyweights" such as Scandinavia, Switzerland, and the United Kingdom.
Oct 01, 2004
BioPharm International
By BioPharm International Editors
We've gone beyond the days when corporate America's idea of a healthy outing was a company softball game complete with beer and hot dogs.
Sep 01, 2004
BioPharm International
By BioPharm International Editors
The industry entered 2004 with a strong balance sheet — about $16 billion in cash and a wide-open pipeline full of new drugs and products.
Sep 01, 2004
BioPharm International
The concept is not new. Companies comparing performance and practices and then mutually identifying the best solutions to common operational challenges has been a part of business for years. What is different is that this is happening in the biopharmaceutical industry, which, until recently, has been primarily focused on filling the pipeline and on improving the manufacturing processes themselves. This focus was not misguided- the biggest challenge facing biopharmaceutical companies until the last five years was convincing everyone that they were legitimate players that can develop and supply therapeutics consistently, and not isolated success stories.
native1_300x100
lorem ipsum